The Asian Oncology Society 1st Virtual International Conference


 

Residual Disease After Neoadjuvant Therapy - Updates on KATHERINE Trial in HER2+ eBC: Adjuvant T-DM1 vs. Trastuzumab

1,325 views
February 18, 2021
2 Comments
Login to view comments. Click here to Login